In the following video, Motley Fool health-care analyst David Williamson highlights a potential new threat to an entire class of multibillion-dollar drugs. The drug group, which treats type 2 diabetes, could be linked to pancreatitis, a very serious inflammation of the pancreas that can lead to pancreatic cancer. David tells investors how several companies, such as Merck (MRK 0.15%), Bristol-Myers Squibb (BMY 1.84%) and AstraZeneca (AZN -0.75%) could be affected if the link is confirmed, and how serious the damage could be financially.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.